This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, H. Articles by Burrows, F. Search for Related Content PubMed PubMed Citation Articles by Zhang, H. Articles by Burrows, F.

Research Articles: Therapeutics

Identification of new biomarkers for clinical trials of Hsp90 inhibitors

Conforma Therapeutics Corp., San Diego, California

Requests for reprints: Francis Burrows, Conforma Therapeutics Corp., 9393 Towne Center Drive, Suite 240, San Diego, CA 92121. Phone: 858-795-0104; Fax: 858-857-0343. E-mail: fburrows{at}conformacorp.com

The selective heat shock protein 90 (HSP90) inhibitor 17-allyamino-17-demethoxygeldanamycin (17-AAG) is currently in phase I/II clinical studies at numerous institutions. Heretofore, the biomarkers to detect 17-AAG bioactivity (Hsp70, Raf-1, and cyclin-dependent kinase 4) had to be analyzed by Western blot of cellular samples, either from tumor biopsies or peripheral blood leukocytes, a method that is both laborious and invasive. We have identified two new biomarkers [insulin-like growth factor binding protein-2 (IGFBP2) and HER-2 extracellular domain] that can be readily detected in patient sera by ELISA. Both secreted proteins are derived from or regulated by Hsp90 client proteins, raising hopes that they might be sensitive serum markers of HSP90 inhibitor activity. Several structurally unrelated HSP90 inhibitors dose-dependently decreased secretion of both IGFBP-2 and HER-2 extracellular domain into culture medium, and both proteins were more sensitive to HSP90 inhibitors than previously identified biomarkers. In sera from BT474 tumor-bearing mice, both IGFBP-2 and HER-2 extracellular domain were down-regulated by 17-AAG in a time-dependent and dose-dependent manner, coincident with the degradation of HER-2 and attenuation of AKT activity in the tumors. Furthermore, IGFBP-2 levels at the end of treatment correlated with residual tumor load, suggesting that IGFBP-2 might serve as an early indicator of therapeutic response. In addition, we also found that both IGFBP-2 and HER-2 extracellular domain levels are elevated in patient sera from several cancer types, suggesting that these novel secreted biomarkers could be valuable pharmacodynamic tools in clinical trials of HSP90 inhibitors. [Mol Cancer Ther 2006;5(5):1256–64]

¹ H. Zhang, et al. Dimeric ansamycins: a new class of antitumor Hsp90 inhibitors with a distinct mode of action, submitted for publication.

Received 12/22/05; revised 2/ 3/06; accepted 3/ 2/06.

This article has been cited by other articles:

				A. S. Martins, J. L. Ordonez, A. Garcia-Sanchez, D. Herrero, V. Sevillano, D. Osuna, C. Mackintosh, G. Caballero, A. P. Otero, C. Poremba, et al. A Pivotal Role for Heat Shock Protein 90 in Ewing Sarcoma Resistance to Anti-Insulin-like Growth Factor 1 Receptor Treatment: In vitro and In vivo Study Cancer Res., August 1, 2008; 68(15): 6260 - 6270. [Abstract] [Full Text] [PDF]

				A. Maloney, P. A. Clarke, S. Naaby-Hansen, R. Stein, J.-O. Koopman, A. Akpan, A. Yang, M. Zvelebil, R. Cramer, L. Stimson, et al. Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Cancer Res., April 1, 2007; 67(7): 3239 - 3253. [Abstract] [Full Text] [PDF]

				J. L. Eiseman, J. Guo, R. K. Ramanathan, C. P. Belani, D. B. Solit, H. I. Scher, S. P. Ivy, E. G. Zuhowski, and M. J. Egorin Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors Clin. Cancer Res., April 1, 2007; 13(7): 2121 - 2127. [Abstract] [Full Text] [PDF]

				R. Mehrian-Shai, C. D. Chen, T. Shi, S. Horvath, S. F. Nelson, J. K. V. Reichardt, and C. L. Sawyers Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer PNAS, March 27, 2007; 104(13): 5563 - 5568. [Abstract] [Full Text] [PDF]

				R. K. Ramanathan, M. J. Egorin, J. L. Eiseman, S. Ramalingam, D. Friedland, S. S. Agarwala, S. P. Ivy, D. M. Potter, G. Chatta, E. G. Zuhowski, et al. Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers Clin. Cancer Res., March 15, 2007; 13(6): 1769 - 1774. [Abstract] [Full Text] [PDF]

				S. A. Lang, D. Klein, C. Moser, A. Gaumann, G. Glockzin, M. H. Dahlke, W. Dietmaier, U. Bolder, H. J. Schlitt, E. K. Geissler, et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo Mol. Cancer Ther., March 1, 2007; 6(3): 1123 - 1132. [Abstract] [Full Text] [PDF]